ERBB2 and breast carcinoma: Growth inhibition induced by CP, and AP after 48, and 72 h treatments in three human Breast cancer cell lines including MDA-MB-231 (ER−/PR−/HER-2-), MCF-7, and T47D (ER+/PR+, HER-2-), and non-tumorigenic fibroblast L929 cells was evaluated.